Sagimet Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021
Revenue	2	0	0
Gross Profit	2	0	0
Selling, General & Admin	12.96	6.14	4.38
Research & Development	19.78	24.92	19.34
Operating Expenses	32.74	31.06	23.72
Operating Income	-30.74	-31.06	-23.72
Other Expense / Income	-2.86	-0.56	0.72
Pretax Income	-27.88	-30.5	-24.44
Net Income	-27.88	-30.5	-24.44
Shares Outstanding (Basic)	10	0	10
Shares Outstanding (Diluted)	10	0	10
Shares Change	5565.90%	-98.11%	-
EPS (Basic)	-2.66	-165.20	-2.51
EPS (Diluted)	-2.66	-165.20	-2.51
Free Cash Flow	-23.77	-24.49	-21.71
Free Cash Flow Per Share	-2.27	-132.65	-2.23
Gross Margin	100.00%	-	-
Operating Margin	-1537.00%	-	-
Profit Margin	-1393.80%	-	-
Free Cash Flow Margin	-1188.30%	-	-
EBITDA	-27.74	-30.37	-24.31
EBITDA Margin	-1386.85%	-	-
Depreciation & Amortization	0.14	0.13	0.13
EBIT	-27.88	-30.5	-24.44
EBIT Margin	-1393.80%	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).